Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Collaboration expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

CRISPR Therapeutics

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

CRISPR Therapeutics AG (CRSP) closed at $57.19 in the latest trading session, marking a +1.69% move from the prior day.

CRISPR Therapeutics AG (CRSP) Increases Despite Market Slip: Here's What You Need to Know

On CRISPR Therapeutics' (CRSP) second-quarter 2024 earnings call, investors' focus is likely to be on the sales numbers of its newly approved gene therapy, Casgevy, and other pipeline updates.

Is a Beat in the Cards for CRISPR (CRSP) in Q2 Earnings?

Beam Therapeutics

Vertex Pharmaceuticals

Gene editing stocks represent one of the biggest investing trends in biopharma in recent years. The gene editing field employs advanced technologies to edit the DNA of different organisms, thereby opening up possibilities for transformative treatment options.

3 Gene Editing Stocks Shaping the Future of Medicine

Viking Therapeutics

CRISPR Therapeutics now has its first product on the market. Zealand Pharma has two promising candidates targeting the huge obesity and MASH/NASH markets.

3 Monster Stocks in the Making to Buy Right Now

Intellia Therapeutics

Gene editing stocks are often biopharmaceutical companies. At these firms, scientists use technology to change the DNA of organisms such as plants, bacteria and animals.

3 Gene Editing Stocks That Could Grow Your Wealth

Editas Medicine

Gene-editing stocks are a promising investment because the field is steadily advancing in the areas of medicine and biotechnology.  Examples include CRISPR and other gene-editing technologies.

3 Gene-Editing Stocks That Could Be Multibaggers in the Making: July Edition

ADMA Biologics

Halozyme Therapeutics

Jazz Pharmaceuticals

Investing in biotech stocks can be rewarding. Not just because these stocks have the potential to produce meaningful gains in your portfolio, but also because when you invest in them, you're investing in companies that are working to treat or heal medical ailments that cause issues for people around the world.

Add These 5 Hot Biotech Stocks In July

CRISPR Therapeutics (CRSP) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

CRISPR Therapeutics (CRSP) Moves 9.2% Higher: Will This Strength Last?

CRISPR Therapeutics and Vertex Pharmaceuticals are partners in one particular program, and they recently won approval for the gene-editing treatment Casgevy. Beyond Casgevy, Vertex has a billion-dollar portfolio of products; Casgevy marks CRISPR Therapeutics' first product approval.

Could CRISPR Therapeutics Become the Next Vertex Pharmaceuticals?

Ocugen, Inc.

CRISPR Therapeutics could ride the wave of its first approval to deliver solid performance over the long run. Despite decent clinical progress, Ocugen remains a high-risk play that has yet to show its long-run potential.

1 Biotech Stock to Buy Hand Over Fist and 1 to Avoid

Aclaris Therapeutics

Outlook Therapeutics Inc

Trading volume spikes in beaten-down stocks often signal a bottom for prices investors can bank on. The problem is that beaten-down stocks are usually in that position for a good reason, so it helps if there is a catalyst for higher share prices in addition to the trading volume.

3 Beaten Down Pharmaceuticals With Catalysts for Higher Prices

CRISPR Therapeutics AG (CRSP) closed at $55.56 in the latest trading session, marking a +0.96% move from the prior day.

Here's Why CRISPR Therapeutics AG (CRSP) Gained But Lagged the Market Today

CRISPR technology, or Clustered Regularly Interspaced Short Palindromic Repeats, is a revolutionary gene-editing tool that allows scientists to make precise modifications to the DNA of living organisms. It's one of the hottest trends in the stock market today, so I've made a list of three of the most profitable CRISPR stocks to consider.

3 Profitable CRISPR Stocks Earning Analysts' Praise

Archer Aviation

Bandwidth

EHang Holdings Ltd - ADR

Ouster, Inc

StoneCo

Upstart Holdings

Growth stocks have been driving the market for most of its history, but the trends have only accelerated recently. Investors are willing to slap a higher and higher premium on these growth stocks as long as they can beat earnings and keep their growth figures high.

7 Growth Stocks to Invest $500 In and Cash Out $100K by 2030

Artificial intelligence stocks will be the choice of growth-oriented investors for years to come. But if you're a buy-and-hold investor with above-average patience, this is a time to look for undervalued gene editing stocks.

The 3 Most Undervalued Gene Editing Stocks to Buy in July 2024

CRISPR Therapeutics AG investors have endured a challenging bear market decline. CRSP's buying momentum has waned as it struggles to stay above the $50 support level. Crispr's pipeline is mainly in the early stages, with Casgevy being the only commercially approved program.

Crispr Therapeutics: Beaten Down But Not Broken

Imagine this: you walk into a hospital for a procedure. You expect a long, traditional surgery with a lengthy recovery.

Forget Intuitive Surgical: This Stock Is the Next Millionaire Maker

Schrodinger 

Gene editing utilizes enzymes that cut part of the DNA strand, allowing the insertion of replacement DNA. Several approaches to gene editing have been developed, the most well-known of which is CRISPR-Cas9.

3 Top-Rated Gene Editing Stocks Actually Making Money

With the progression of modern medicine, and the continuous discoveries in the realm of gene editing, investing early in the technology could be a game changer for long-term returns if selecting the best gene editing stocks to buy. That's because unlike more standard therapeutics such as antibiotics, antivirals and vaccines gene editing is a permanent solution most of the time.

You've Been Warned! 3 Gene Editing Stocks to Buy Now or Regret Forever.

Ginkgo Bioworks Holdings

Cassava Sciences Inc

In 2024, the iShares Biotechnology ETF (NASDAQ: IBB ) is up just over 1.5%. If you're looking for steady, dividend-paying stocks, you can find a number of biotech stocks to buy from the holdings in this fund.

Rags to Riches: 3 Biotech Stocks That Could Make Early Investors Rich

Eli Lilly

Novavax

Biotech stocks to buy now reflect a more dynamic shift in investor focus of late.Over the past few years, the biotech space attracted plenty of investor interest, driven by the Covid-19 pandemic. Global vaccine sales for the crippling virus were upwards of $142 billion from 2020 to 2023.

You've Been Warned! 3 Biotech Stocks to Buy Now or Regret Forever.

CRISPR Therapeutics is a gene-editing pioneer. Despite its landmark regulatory approvals with Casgevy, its shares have failed to excite the investment community.

Is CRISPR Therapeutics Stock a Buy? One Analyst Thinks the Biotech Is "Very Undervalued.

Regeneron Pharmaceuticals

In the world of investing, biotech stocks represent a unique blend of high risk and high reward. After a period of volatility in the broader markets in 2022 and 2023, biotech stocks are now drawing attention for their potential to deliver substantial long-term returns.

3 Biotech Stocks That Could Make Your Grandchildren Rich

Gene editing is a game-changer. With it, we can remove cells from your body, edit them, and then reintroduce them back into the body.

Rags to Riches: 3 Gene Editing Stocks That Could Make Early Investors Rich

CRISPR Therapeutics AG (CRSP) closed at $56.63 in the latest trading session, marking a +1.22% move from the prior day.

News for CRISPR Therapeutics Stock (CRSP)